American Capital Management Inc. Acquires 92,986 Shares of Cambrex Co. (CBM)
American Capital Management Inc. increased its holdings in shares of Cambrex Co. (NYSE:CBM) by 16.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 658,644 shares of the biotechnology company’s stock after acquiring an additional 92,986 shares during the quarter. Cambrex comprises about 1.9% of American Capital Management Inc.’s holdings, making the stock its 23rd largest position. American Capital Management Inc.’s holdings in Cambrex were worth $31,615,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. lifted its position in shares of Cambrex by 0.5% in the 2nd quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock worth $240,409,000 after purchasing an additional 20,652 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Cambrex by 1.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,343,468 shares of the biotechnology company’s stock worth $73,891,000 after purchasing an additional 13,214 shares during the period. FMR LLC lifted its position in shares of Cambrex by 19.1% in the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock worth $63,971,000 after purchasing an additional 171,559 shares during the period. State Street Corp lifted its position in shares of Cambrex by 5.1% in the 2nd quarter. State Street Corp now owns 779,820 shares of the biotechnology company’s stock worth $46,600,000 after purchasing an additional 37,669 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Cambrex by 3.7% in the 2nd quarter. Northern Trust Corp now owns 566,302 shares of the biotechnology company’s stock worth $33,837,000 after purchasing an additional 19,955 shares during the period.
A number of research analysts have recently issued reports on CBM shares. William Blair started coverage on shares of Cambrex in a research report on Tuesday, January 16th. They issued an “outperform” rating on the stock. Craig Hallum restated a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. Finally, Zacks Investment Research upgraded shares of Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Cambrex currently has a consensus rating of “Hold” and a consensus target price of $60.50.
Cambrex (NYSE:CBM) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.08. The company had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. Cambrex’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.47 EPS. analysts predict that Cambrex Co. will post 2.97 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “American Capital Management Inc. Acquires 92,986 Shares of Cambrex Co. (CBM)” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://theolympiareport.com/2018/01/23/american-capital-management-inc-acquires-92986-shares-of-cambrex-co-cbm.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.